<DOC>
	<DOC>NCT02295969</DOC>
	<brief_summary>Safety and tolerability of ORALAIR in children 5 to 9 years of age during the first 30 days of treatment.</brief_summary>
	<brief_title>Observational Study of OralairÂ® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis</brief_title>
	<detailed_description>The purpose of this study is to further describe the safety and tolerability of ORALAIR tablets in children 5 to 9 years of age with grass-pollen-induced allergic rhinitis with or without conjunctivitis. Patients are followed for safety and tolerability during the first 30 treatment days.</detailed_description>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Allergen immunotherapy naive male or female outpatients aged 5 to 9 years (inclusive) prescribed ORALAIR. Patients already participating in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Rhinitis</keyword>
	<keyword>Conjunctivitis</keyword>
	<keyword>Grass pollen</keyword>
	<keyword>Sublingual tablet</keyword>
	<keyword>Allergen immunotherapy</keyword>
	<keyword>Safety</keyword>
</DOC>